AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

FDA's plan to phase out animal testing may hurt Charles River's revenues. The DCF model suggests that CRL presents an ...

Proteins have specific biological functions in cells through conformational changes and interactions. Therefore, precise, in ...

AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells.

The entire process can take weeks, though many companies are working on ways to make it faster and more efficient. In vivo engineering of a patient’s immune cells would avoid this expensive ...

Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

Antibiotic efflux pumps are expressed in all microbes, where they serve as crucial gatekeepers in resisting the cellular ...

Assessing the distribution of a medication in the brain is critical for the treatment of a vast range of neurological ...

Cubosomes with an internal three-dimensional (3D) periodic and porous particulate nanostructure have emerged as a promising drug delivery system for hydrophobic small molecules as well as large ...

Instead of extracting T-cells and engineering them in a lab, researchers have delivered mRNA directly into circulating immune ...